The Attractiveness of Investing In Acadia Pharmaceuticals Inc (ACAD) is Growing

Acadia Pharmaceuticals Inc’s recent filing unveils that its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported $82728.0 on Sep 15 ’25. In the deal valued at $23.65 per share,3,498 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 43,447 shares worth roughly $0.94 million.

Then, GAROFALO ELIZABETH A. sold 1,600 shares, generating $41,560 in total proceeds. Upon selling the shares at $25.98, the Director now owns 25,382 shares.

Before that, Schneyer Mark C. sold 22,000 shares. Acadia Pharmaceuticals Inc shares valued at $554,024 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $25.18 per share. As a result of the transaction, Schneyer Mark C. now holds 40,130 shares, worth roughly $0.86 million.

Deutsche Bank upgraded its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Hold”‘ rating. Guggenheim also remained covering ACAD and has decreased its forecast on January 03, 2025 with a “Neutral” recommendation from previously “Buy” rating.

Price Performance Review of ACAD

On Tuesday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -0.23% to $21.54. Over the last five days, the stock has gained 0.94%. Acadia Pharmaceuticals Inc shares have risen nearly 46.33% since the year began. Nevertheless, the stocks have risen 17.38% over the past one year. While a 52-week high of $26.65 was reached on 08/28/25, a 52-week low of $13.40 was recorded on 04/09/25.

Levels Of Support And Resistance For ACAD Stock

The 24-hour chart illustrates a support level at 21.32, which if violated will result in even more drops to 21.10. On the upside, there is a resistance level at 21.86. A further resistance level may holdings at 22.17.

How much short interest is there in Acadia Pharmaceuticals Inc?

A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2025-09-15, dropping by -2.0 million shares to a total of 7.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 9.98 million shares. There was a decline of -25.03%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.